Quest Diagnostics Incorporated reported financial results for the second quarter ended June 30, 2026, demonstrating robust top- and bottom-line growth that exceeded analyst expectations. Net revenues increased 10.2% to $3.043 billion, compared to $2.761 billion in the prior year, beating the analyst consensus estimate of $2.973 billion by 2.34%. Organic revenue growth was 10.0%. Reported diluted earnings per share (EPS) increased 15.0% to $2.84, while adjusted diluted EPS grew 19.1% to $3.12, surpassing the analyst consensus estimate of $2.83 by 10.25%.

Jim Davis, Chairman, CEO and President, attributed the growth to focused execution across physician, hospital, and consumer channels. "Revenues increased by over 10%, almost all from organic revenue growth across our physician, hospital and consumer channels, and adjusted diluted EPS grew over 19%," Davis stated. "With strong growth and sustained demand for our diagnostic insights, we are again raising our full year guidance."

Operational Highlights

The company advanced its Co-Lab Solutions implementation and joint venture laboratory with Corewell Health in Michigan. It developed new kidney care capabilities through a collaboration with Fresenius Medical Care in the United States. Quest Diagnostics also generated robust revenue growth through questhealth.com and consumer, wearable, and wellness partners.

In Advanced Diagnostics, revenues grew by double digits in several areas, including Quest AD-Detect blood tests for Alzheimer's disease and advanced cardiometabolic and endocrine tests. The company received New York State approval for its Haystack MRD test and became the largest reference lab to utilize Flatiron Health's OncoEMR Molecular Profiling Integration platform for select cancer tests.

Updated Guidance

Based on the favorable resolution of various tax contingencies in the second quarter, Quest Diagnostics raised its full-year 2026 guidance. The company now expects full-year revenues to be between $11.95 billion and $12.05 billion, compared to prior guidance of $11.78 billion to $11.90 billion. This compares to an analyst estimate of $11.851 billion.

Reported diluted EPS is now expected to be between $9.97 and $10.17, up from the prior range of $9.58 to $9.78. Adjusted diluted EPS is expected to be between $11.05 and $11.25, an increase from the previous guidance of $10.63 to $10.83. This compares to an analyst estimate of $10.76. The full-year adjusted effective tax rate is expected to be consistent with 2025.

Financial Performance

Cash provided by operations for the six months ended June 30, 2026, was $875 million, compared to $858 million in the prior year. Capital expenditures for the six-month period were $252 million, an increase from $225 million. As of June 30, 2026, the company had $1.3 billion remaining available under its share repurchase authorization.

Baird analyst Eric Coldwell has maintained a Neutral rating on Quest Diagnostics while raising the price target to $236 from $232. The adjustment signals a modestly improved valuation outlook for the company despite the unchanged stance on the stock.

The revised price target of $236 represents an increase from the previous target of $232. Quest Diagnostics operates in the diagnostics sector, providing testing services and insights.

The Neutral rating suggests that the analyst sees limited upside potential relative to the current market price, even with the higher target. Investors will monitor the company's performance against this new benchmark.